Although the combination of a TKT inhibitor and cisplatin did not show synergy in HNSCC cells, targeting TKT may have a synergistic interaction with other approved drugs; further research is needed to explore additional combinations. The gene discussed is TKT; the disease is head and neck squamous cell carcinoma.